The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It

5-MeO-DMT has 164 patents in the tracker, but patent ownership does not align neatly with clinical leadership. Turtle Bear Holdings leads with 10 granted and 15 pending patents, mostly broad extract composition claims, while AtaiBeckley holds 8 granted and 8 pending patents supporting BPL-003, which reported a 55% next-day response rate in Phase 2b and received FDA Breakthrough Therapy Designation. GH Research is the outlier: its GH001 inhaled 5-MeO-DMT achieved a 57.7% remission rate versus 0% for placebo in Phase 2b treatment-resistant depression, yet it has only one granted US patent and 26 pending applications. A European patent improves its global position. The comparison raises questions about how much US patent strength matters if clinical success, regulatory exclusivity, and approval arrive first. The report is business and regulatory analysis, not medical advice, and notes that no compound discussed is FDA-approved for the listed indications.